Pharmacogenetics of anthracyclines.
Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic. Childhood cancer survivors treated with anthracyclines often undergo cardiac complications which are influenced by genetic variations of the patients. The scientific literature comprises numerous investigations in the subject of the pharmacogenetics of anthracyclines. In this review, we provide a comprehensive overview of this research topic. Genetic variants are proposed targets in the personalized treatment in order to individualize dosing and therefore reduce side effects.
Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.
Judit C
JC
Sági
Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.
Nóra
N
Kutszegi
Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.
Andrea
A
Kelemen
Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.
Lili E
LE
Fodor
Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.
András
A
Gézsi
Second Department of Pediatrics, Semmelweis University, H-1094 Budapest, Tűzoltó utca 7-9, Hungary.
Gábor T
GT
Kovács
Second Department of Pediatrics, Semmelweis University, H-1094 Budapest, Tűzoltó utca 7-9, Hungary.
Dániel J
DJ
Erdélyi
Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.|Central Laboratory, Heim Pal Children Hospital, H-1089 Budapest, Üllői út 86, Hungary.
Csaba
C
Szalai
Department of Genetics, Cell- and Immunobiology, Semmelweis University, H-1089 Budapest, Nagyvárad tér 4, Hungary.
Ágnes F
ÁF
Semsei
D000818:Animals; D018943:Anthracyclines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic
anthracycline; cancer; cardiotoxicity